NEW FUNDING OPPORTUNITY!
TUCSON, Ariz, January 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. Continue reading
The award will go towards the development of CTX-001 in preparation for clinical studies.Continue reading
Did you know that the Arizona Legislature has a system that makes it possible for the people of Arizona to provide feedback on proposed policy as it moves through the process? It is called the Request to Speak System (RTS) and your voice matters.Continue reading
Protecting Arizonans at every stage of life at the AZ State Health LabContinue reading
TUCSON, AZ. — The University of Arizona Center for Innovation (UACI) is pleased to announce the UACI Sponsored Launch Fueled by Spencer Fane LLP competition providing the winning startup team with resources, facilities, services and expert guidance to grow their business.Continue reading
SB1019: appropriation; health innovation trust fund received its first hearing in Arizona’s Senate Health and Human Services Committee on January 16, 2024. As currently written, SB1019 appropriates $5M to the Arizona Health Innovation Trust Fund, and declares that it is the Legislature’s intent that the Fund, consisting of monies appropriated by the Legislature, gifts or grants donated or given to the Fund and earnings from the Fund, steadily grow to ultimately maintain a permanent endowment balance of at least $200 million.
SB1019 received a unanimous do pass recommendation. It now is eligible for consideration by the Senate Appropriations Committee.Continue reading
NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.”
Continue reading
Researchers say the genetically engineered stem cells also could pave the way for new regenerative medicine treatments for diseases such as Type 1 diabetes.Continue reading
TUCSON, Ariz., January 11, 2024 — Critical Path Institute (C-Path) today announced the launch of a task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.Continue reading